Coronavirus (COVID-19) Update
Message from NYGC Leadership
As we all navigate the uncharted waters that the COVID-19 virus pandemic presents, the New York Genome Center (NYGC) remains focused on continuing our critical research. We are committed to advancing new insights for patients with neurodegenerative disease, neuropsychiatric disease, and cancer and are exploring ways in which our expertise in genomics can help in the research of the novel coronavirus known as SARS-CoV-2.
The safety and health of our NYGC team and community is our top priority. We have implemented internal safety procedures and policies according to the latest CDC, New York State, and City directives and recommendations. Early on, we implemented precautionary measures including asking most of our team to work remotely to protect the safety and security of our staff, collaborators, and local community. Our sequencing and clinical laboratories are operating effectively with a small number of essential staff onsite. We have implemented staggered hours to enable social distancing in our workplace, and our laboratories and common areas are undergoing high frequency, intensive cleanings.
We are not allowing any visitors at this time, unless they are essential to our operation. Meetings with non-essential visitors, including collaborators, vendors, consultants, contractors, speakers and prospective hires, will be “virtual” until further notice. Any visitors authorized to come onsite are required to follow the same viral infection prevention measures as our staff, including social distancing.
Though we are making many adjustments to the way we work, we are maintaining the momentum of our scientific collaborations and convening our working groups and lectures virtually. Due to the fluidity of the situation, we will review our virtual meetings policy regularly and post all upcoming event information on the Events section of our website.
With our best wishes for community safety and good health,
|Tom Maniatis, PhD
Evnin Family Scientific Director and Chief Executive Officer
|Cheryl A. Moore
President and Chief Operating Officer